| [1] |
Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus[J]. Curr Opin Rheumatol, 2013, 25(5): 616-622.
|
| [2] |
Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE？[J]. Int J Rheum Dis, 2015, 18(2): 182-191.
|
| [3] |
Hollander MC, Sage JM, Greenler AJ, et al. International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2013, 65(9): 1416-1423.
|
| [4] |
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
|
| [5] |
Thakral A, Klein-Gitelman MS. An update on treatment and management of pediatric systemic lupus erythematosus[J]. Rheumatol Ther, 2016, 3(2): 209-219.
|
| [6] |
Moulton VR, Suarez-Fueyo A, Meidan E, et al. Pathogenesis of human systemic lupus erythematosus: a cellular perspective[J]．Trends Mol Med, 2017, 23(7): 615-635. .
|
| [7] |
Webb R, Kelly JA, Somers EC, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients[J]. Ann Rheum Dis, 2011, 70(1): 151-156.
|
| [8] |
Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE[J]. Clin Immunol, 2013, 148(3): 303-312.
|
| [9] |
Sun XG, Tao JH, Xiang N, et al. Negative correlation between miR-326 and Ets-1 in regulatory T cells from new-onset SLE patients[J]. Inflammation, 2016, 39(2): 822-829.
|
| [10] |
Lu MC, Lai NS, Chen HC, et al. Decreased microRNA (miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis[J]. Clin Exp Immunol, 2013, 171(1): 91-99.
|
| [11] |
Husakova M. MicroRNAs in the key events of systemic lupus erythematosus pathogenesis[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2016, 160(3): 327-342.
|
| [12] |
Jacob CO, Reiff A, Armstrong DL, et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform[J]. Arthritis Rheum, 2007, 56(12): 4164-4173.
|
| [13] |
Armstrong DL, Reiff A, Myones BL, et al. Identification of new SLE-associated genes with a two-step Bayesian study design[J]. Genes Immun, 2009, 10(5): 446-456.
|
| [14] |
Dudhgaonkar S, Ranade S, Nagar J, et al. Selective IRAK4 inhibition attenuates disease in murine lupus models and demonstrates steroid sparing activity[J]. J Immunol, 2017, 198(3): 1308-1319.
|
| [15] |
Kasturi S, Sammaritano LR. Corticosteroids in lupus[J]. Rheum Dis Clin North Am, 2016, 42(1): 47-62.
|
| [16] |
Lam NC, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management[J]. Am Fam Physician, 2016, 94(4): 284-294.
|
| [17] |
Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus[J]. Rheumatology, 2014, 53(8): 1470-1476.
|
| [18] |
Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis[J]. Ann Rheum Dis, 2012, 71(11): 1771-1782.
|
| [19] |
Sun L, Liu M, Li R, et al. Hydroxychloroquine, a promising choice for coronary artery disease？[J]. Med Hypotheses, 2016, 93: 5-7.
|
| [20] |
Shulman S, Wollman J, Brikman S, et al. Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists[J]. Lupus, 2017, 26(3): 277-281.
|
| [21] |
Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy[J]. JAMA Ophthalmol, 2014, 132(9): 1105-1112.
|
| [22] |
Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus[J]. Arthritis Care Res (Hoboken), 2012, 64(3): 375-383.
|
| [23] |
Tornatore KM, Meaney CJ, Wilding GE, et al. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients[J]. Clin Pharmacokinet, 2015, 54(4): 423-434.
|
| [24] |
Sinha R, Raut S. Pediatric lupus nephritis: management update[J]. World J Nephrol, 2014, 3(2): 16-23.
|
| [25] |
Houssiau FA, Vasconcelos C, D′Cruz D, et al. The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide[J]. Ann Rheum Dis, 2010, 69(1): 61-64.
|
| [26] |
Oktem O, Guzel Y, Aksoy S, et al. Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility[J]. Obstet Gynecol Surv, 2015, 70(3): 196-210.
|
| [27] |
Thompson AJ, Newman WG, Elliott RA, et al. The cost- effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine[J]. Value Health, 2014, 17(1): 22-33.
|
| [28] |
Liu F, Ma R, Riordan SM, et al. Azathioprine, mercaptopurine, and 5-aminosalicylic acid affect the growth of IBD-associated campylobacter species and other enteric microbes[J]. Front Microbiol, 2017, 8: 527.
|
| [29] |
Alexander T, Arnold R, Hiepe F. Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus[J]. Z Rheumatol, 2016, 75(8): 770-779.
|
| [30] |
Reddy V, Martinez L, Isenberg DA, et al. Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: long-term effects on serum immunoglobulins[J]. Arthritis Care Res (Hoboken), 2017, 69(6): 857-866.
|
| [31] |
Jordan NP, D′Cruz DP. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus[J]. Expert Opin Drug Metab Toxicol, 2015, 11(10): 1635-1645.
|
| [32] |
Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness[J]. Ther Adv Musculoskelet Dis, 2017, 9(3): 75-85.
|
| [33] |
Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus[J]. Lupus, 2016, 25(10): 1086-1096.
|
| [34] |
Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging[J]. Ann N Y Acad Sci, 2015, 1346(1): 33-44.
|
| [35] |
Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus[J]. J Autoimmun, 2014, 54: 60-71.
|